Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Learn about Deep Track Capital's proxy fight with Dynavax (DVAX) and their push to prioritize Heplisav's growth.

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.